Functional interplay between liver X receptor and AMP‐activated protein kinase α inhibits atherosclerosis in apolipoprotein E‐deficient mice − a new anti‐atherogenic strategy
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Background and Purpose: The liver X receptor (LXR) agonist T317 reduces atherosclerosis but induces fatty liver. Metformin activates energy metabolism by activating AMPKα. In this study, we determined if interactions between metformin and T317 could inhibit atherosclerosis without activation of hepatic lipogenesis. Experimental Approach: Apolipoprotein E‐deficient mice were treated with T317, metformin or both agents, in a high‐fat diet for 16 weeks. Then, samples of aorta, liver, macrophage and serum were collected to determine atherosclerotic lesions, fatty liver, lipid profiles and expression of related proteins. Techniques used included immunohistochemistry, histology, qRT‐PCR and Western blot. Key Results: T317 inhibited en face and aortic root sinus lesions, and the inhibition was further enhanced by addition of metformin. Co‐treatment with metformin and T317 increased lesion stability, by increasing collagen content, and reducing necrotic cores and calcification. Formation of macrophages/foam cells and their accumulation in arterial wall were inhibited by the co‐treatment, which was accompanied by increased ABCA1/ABCG1 expression, reduced monocyte adhesion and apparent local proliferation of macrophages. Metformin blocked T317‐induced fatty liver by inhibiting T317‐induced hepatic LXRα nuclear translocation and expression of lipogenic genes and by activating AMPKα. Moreover, co‐treatment with T317 and metformin improved triglyceride metabolism by inducing expression of adipose triglyceride lipase, hormone‐sensitive lipase, PPARα and carnitine acetyltransferase and by inhibiting acyl‐CoA:diacylglycerol acyltransferase 1 expression. Conclusions and Implications: Co‐treatment with T317 and metformin inhibited the development of atherosclerosis without activation of lipogenesis, suggesting that combined treatment with T317 and metformin may be a novel approach to inhibition of atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Macrophages in the Pathogenesis of Atherosclerosis
Moore, K. J., & Tabas, I. (2011) · Cell · doi:10.1016/j.cell.2011.04.005 · Cited by 2,669
Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
McGrath, J. C., & Lilley, E. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12955 · Cited by 1,321
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284 · cited 1×
“The anti-diabetic actions of metformin include suppressing hepatic glucose production, increasing insulin sensitivity, enhancing peripheral glucose uptake and releasing insulin-suppressed fatty acid oxidation (Hundal et al., 2000; Collier et al., 2006; Rena et al., 2013; Madiraju et al., 2014).”
BackgroundSelf-citationMechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052 · cited 1×
“The anti-diabetic actions of metformin include suppressing hepatic glucose production, increasing insulin sensitivity, enhancing peripheral glucose uptake and releasing insulin-suppressed fatty acid oxidation (Hundal et al., 2000; Collier et al., 2006; Rena et al., 2013; Madiraju et al., 2014).”
BackgroundMaruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682 · cited 1×
“Metformin is a first-line treatment for Type 2 diabetes (Maruthur et al., 2016).”
BackgroundHDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis
Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, T., & Wang, N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.03.001 · Cited by 540
Metformin Inhibits Proinflammatory Responses and Nuclear Factor-κB in Human Vascular Wall Cells
Isoda, K., Young, J. L., Zirlik, A., MacFarlane, L. A., Tsuboi, N., Gerdes, N., Schönbeck, U., & Libby, P. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000201938.78044.75 · Cited by 499
Molecular mechanism of action of metformin: old or new insights?
Rena, G., Pearson, E. R., & Sakamoto, K. (2013) · Diabetologia · doi:10.1007/s00125-013-2991-0 · Cited by 479
Cited by
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
Self-citationTomita, I., Kume, S., Sugahara, S., Osawa, N., Yamahara, K., Yasuda-Yamahara, M., Takeda, N., Chin-Kanasaki, M., Kaneko, T., Mayoux, E., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.020 · Cited by 376
Chen, Q., Wang, S., Bao, R., Wang, D., Wu, Y., Zhang, Y., Liu, M., & Wang, T. (2024) · Chinese Medicine · doi:10.1186/s13020-023-00876-9 · Cited by 16
Metadata
- Authors
- Ma, C., Zhang, W., Yang, X., Liu, Y., Liu, L., Feng, K., Zhang, X., Yang, S., Sun, L., Yu, M., Yang, J., Li, X., Hu, W., Miao, R. Q., Zhu, Y., Li, L., Han, J., Chen, Y., & Duan, Y.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2018-03-23
- Volume
- 175
- Issue
- 9
- Pages
- 1486-1503
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2789638516
- Cited by
- 48
- References
- 13
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.